HEARTLINE HSM Genoa Cardiology Meeting - Aristea
HEARTLINE HSM Genoa Cardiology Meeting - Aristea
HEARTLINE HSM Genoa Cardiology Meeting - Aristea
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
11<br />
Primary Safety Endpoint included:<br />
• Device embolization requiring retrieval;<br />
• Pericardial effusion requiring intervention;<br />
• Cranial bleeds and gastrointestinal bleeds;<br />
• Any bleed that requires ≥ 2uPRBC;<br />
Eighty-seven percent of implanted subjects were able to cease warfarin at days and the<br />
rate further increased at later time points; reasons for remaining on warfarin therapy after<br />
-days were observation of ow in the LAA (n = 0), physician order (n = 1 ), other<br />
reasons (n = 9).<br />
As far as safety endpoints are concerned events in device group were classied as<br />
ischemic stroke: they were all periprocedural and extended hospitalization by 7 days; three<br />
events were related to air embolism; one hemorrhagic stroke in device group vs 6 in control<br />
group were adjudicated. By note, device events occurred 1 days post implant while patient<br />
was on warfarin and /6 stroke events in control group patients resulted in death.<br />
In conclusion, in AF patients who were candidates for warfarin therapy, device closure of<br />
the LAA using the Watchman device (Atritech, Plymouth, MN) was associated with a<br />
reduction in hemorrhagic stroke risk vs warfarin, and all-cause stroke and all-cause<br />
mortality outcomes were noninferior to warfarin. 10<br />
Safety events, particularly pericardial effusion, were more common in the device group, but<br />
these have decreased over time with procedural modications and enhanced training, the<br />
researchers noted.<br />
Indications<br />
Currently, when to close LAA?<br />
Patients with:<br />
• Permanent atrial brillation<br />
• High risk of stroke<br />
And with:<br />
• Contraindication to warfarin<br />
• High risk of bleeding with OAC<br />
• Difcult to maintain INR within the therapeutic range<br />
• Poor compliance<br />
• Difculty to manage the patient because of logistic problems<br />
AMPLATZER ® Cardiac Plug (AGA Medical Corporation)<br />
The AMPLATZER Cardiac Plug (ACP; Figure 2) is a transcatheter self-expanding device<br />
constructed from a nitinol mesh and polyester patch, ACP consists of a lobe and a disc<br />
connected by a central waist.<br />
The ACP is available in 8 sizes: 16, 18, 20, 22, 2 , 26, 28, and 0 mm.